Dual suppression of stemness and redox adaptation in glioblastoma through filaggrin upregulation by an abiraterone-based HDAC inhibitor
Abstract Background Temozolomide (TMZ) resistance in glioblastoma (GBM) remains a critical barrier to treatment success, driven by O6-methylguanine-DNA methyltransferase (MGMT) overexpression, glioma stem cell (GSC) persistence, and redox adaptation. Methods We developed cp8, a first-in-class abirat...
Sparad:
| Huvudupphov: | , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
BMC
2026-04-01
|
| Serie: | Journal of Biomedical Science |
| Ämnen: | |
| Länkar: | https://doi.org/10.1186/s12929-026-01241-2 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|